Clinical practice recommendations for primary hyperoxaluria: an expert consensus statement from ERKNet and...

Primary hyperoxaluria remains a rare and complex condition, often diagnosed late due to its variable symptoms and the lack of awareness among clinicians. While prior research has established the role of oxalate overproduction in kidney damage, gaps remain in understanding optimal management strategies. No prior work had resolved how to best integrate new therapies into clinical practice. This uncertainty drove the need for updated guidelines. The rarity of the disease complicates data collection and treatment standardization. Existing evidence has not fully addressed the challenges of managing patients with kidney failure. The emergence of RNA interference therapies has introduced new possibilities. However, the integration of these therapies into routine care requires consensus-based guidance.

The aim of this expert consensus statement is to provide updated clinical recommendations for the management of primary hyperoxaluria. The study addresses the challenge of integrating new therapies with established treatment options. It focuses on improving diagnostic accuracy and patient outcomes. The motivation stems from recent advances in RNA interference and improved survival data in transplanted patients. The goal is to standardize care across multidisciplinary teams. The consensus includes statements on diagnosis, treatment, and follow-up. The study seeks to bridge the gap between emerging evidence and clinical practice. It aims to guide clinicians in managing a complex and rare disease.

The consensus development group included specialists in nephrology, urology, biochemistry, and genetics. They reviewed existing evidence on primary hyperoxaluria. The group formulated statements based on expert opinion and available data. The process involved a systematic review of published literature. Statements were graded according to the strength of evidence and consensus. The group considered outcomes from patients with infantile oxalosis and transplanted patients. They evaluated the role of conventional therapies like dialysis and transplantation. The final statements were endorsed by representatives from OxalEurope, ESPN, ERKNet, and ERA.

The consensus group produced 48 statements covering diagnosis and management of PH. These statements address conventional therapies, new RNA interference treatments, and follow-up protocols. The recommendations include guidance on conservative therapy and dialysis. They also provide insights into the management of PH1, PH2, and PH3. The statements emphasize the importance of early diagnosis and multidisciplinary care. They highlight the potential of RNA interference therapies in reducing oxalate production. The group provided practical advice on patient monitoring and long-term outcomes. The statements aim to improve clinical decision-making and patient outcomes.

The authors propose that updated guidelines are essential to reflect recent developments in PH management. They suggest that RNA interference therapies offer promising new treatment options. The authors emphasize the need for a multidisciplinary approach to diagnosis and care. They highlight the importance of early diagnosis in improving patient outcomes. The authors propose that dialysis and transplantation remain key treatment options. They suggest that follow-up protocols should be standardized across centers. The authors propose that patient monitoring should include regular assessment of oxalate levels. They suggest that these statements provide a practical framework for clinicians managing PH.